Eurepa (Repaglinide) 0.5mg – 100 tablet

>10%:

Central nervous system: Headache (9% to 11%)

Endocrine & metabolic: Hypoglycemia (16% to 31%)

Respiratory: Upper respiratory tract infection (10% to 16%)

1% to 10%:

Cardiovascular: Ischemia (4%), chest pain (2% to 3%)

Gastrointestinal: Diarrhea (4% to 5%), constipation (2% to 3%)

Genitourinary: Urinary tract infection (2% to 3%)

Hypersensitivity: Hypersensitivity reaction (1% to 2%)

Neuromuscular & skeletal: Back pain (5% to 6%), arthralgia (3% to 6%)

Respiratory: Sinusitis (3% to 6%), bronchitis (2% to 6%)

<1%, postmarketing, and/or case reports: Alopecia, anaphylactoid reaction, blurred vision (transient), cardiac arrhythmia, ECG abnormality, hemolytic anemia, hepatic insufficiency (severe), hepatitis, hypertension, increased liver enzymes, jaundice, leukopenia, myocardial infarction, palpitations, pancreatitis, Stevens-Johnson syndrome, thrombocytopenia, visual disturbance (transient)